Inzaule Seth C, Hamers Raph L, Mukui Irene, Were Kennedy, Owiti Prestone, Kwaro Daniel, Rinke de Wit Tobias F, Zeh Clement
aDepartment of Global Health, Academic Medical Center of the University of Amsterdam, and Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands bKenya Medical Research Institute, Kisumu, Kenya cDepartment of Internal Medicine, Division of Infectious Diseases, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands dNational AIDS & STI Control Programme, Nairobi, Kenya eUS Centers for Disease Control and Prevention, Kisumu, Kenya.
AIDS. 2017 Jun 19;31(10):1495-1498. doi: 10.1097/QAD.0000000000001500.
: We performed a countrywide assessment of HIV drug resistance among 123 patients with virological failure on second-line antiretroviral therapy (ART) in Kenya. The percentage of patients harbouring intermediate-to-high-level resistance was 27% for lopinavir-ritonavir, 24% for atazanavir-ritonavir and 7% for darunavir-ritonavir, and 25% had complete loss of activity to all available first and second-line drugs. Overall, one in four patients failing second-line ART have completely exhausted available antiretrovirals in Kenya, highlighting the need for increased access to third-line drugs.
我们对肯尼亚123例二线抗逆转录病毒治疗（ART）出现病毒学失败的患者进行了全国范围内的HIV耐药性评估。携带中高水平耐药性的患者比例分别为：洛匹那韦-利托那韦27%，阿扎那韦-利托那韦24%，达芦那韦-利托那韦7%，25%的患者对所有可用的一线和二线药物完全失去活性。总体而言，在肯尼亚，四分之一二线ART治疗失败的患者已完全用尽可用的抗逆转录病毒药物，这突出表明需要增加三线药物的可及性。
